Hello, this is Theresa Agnew, CEO of BioGaia, and we are here to present our Q3 2026 results. So from a financial highlights standpoint, our growth excluding currency effects is 23% for the quarter. Our net sales were 400 million SEK and our EBIT margin was 33%. Overall, our net sales, as we said, have grown 23%, excluding currency effects. And if you look at the regions, our EMEA, Europe, Middle East and Africa region increased by 38% excluding currency effects, and the Americas, which includes Latin America as well as North America, increased by 23%. Sales in Asia Pacific increased by 8%, excluding currency effects. Our overall operating profit for the quarter was around 132 MSEK, which is an increase of 54%, and our EBIT margin was 33% compared to 26% last year in the same quarter. Our overall net sales year-to-date reached 1,214 MSEK, with growth excluding currency effects of 16% and an overall year-to-date adjusted EBIT margin of 31%. So to talk about our strategy, we have three main strategic pillars. Our first is what we call grow the core, which is focused on our core health areas of gut health, oral health, and immune health. Our second area is expansion through direct markets, where over the last five years, we have been taking certain markets direct as subsidiaries and driving growth through those markets. And then finally, breakthrough innovation, where these are probiotics we are working on that will create category opportunities where probiotics are not typically used today.
And our foundations are people and culture investing for profitable growth, digital as an enabler, both in the way we go to market with our omnichannel approach, as well as digitizing our business internally to drive more productivity and efficiency; driven by science, which has been a foundation of the company and a very important one for the last 35 years; and sustainable solutions, with a strong focus on driving sustainability in our products as well as how we go to market.
In terms of delivering on our strategy for the quarter, in our grow the core area, as you saw, we have had strong growth across pediatrics and adult health segments. This is supported by Protectis drops, Protectis tablets, and Prodentis. We continue investment in consumer and medical marketing to drive growth in our key markets. Specifically, some of our direct markets, where the combination of medical marketing and consumer marketing is used, are driving our growth above the overall category level. We are strengthening our position in oral health, particularly focusing on Prodentis and especially in the US and Canada. For the quarter, we have seen strong growth in Prodentis in those markets. In terms of expansion through direct markets, we continue our development in our direct markets where this has contributed. Our direct markets have contributed to 38% growth in EMEA. We are expanding distribution in France. We started our direct market in 2025, and over the course of the last year, we have been driving distribution dramatically in France, as well as across some key retailers in the UK, where we are now in Holland & Barrett, which is a major retailer in the UK with our Protectis drops in over 600 stores. We continue our focus on strengthening our BioGaia brand. We are expanding our global reach and as I said previously, we have an omnichannel approach where we make our products available in the channels where the consumer wants to buy, and we surround the consumer with digital marketing through social media, video and so forth. In terms of breakthrough innovation, we had an exciting launch this quarter with BioGaia Colus. It adds to our science-based portfolio in adult gut health. Two years ago, we added a product called Gastric Pure Action into Adult Health, and now this year we are adding BioGaia Colus. This is a unique proprietary strain, L. reuteri BG-R59, and it is supported by two independent, randomized controlled clinical trials. Our initial launch has been in the UK, and this will be followed by rollouts across selected markets globally. In terms of our launches, you can see here the launches that happened in the quarter. One of particular interest is that we have launched a new flavor of our Protectis kids tablets with vitamin D. It's a strawberry flavor and this has been well received in the markets where we're launching this. We continue our rollout of our skincare products, our wash as well as body lotion, into the UK. And we've also launched our BioGaia Aldermis, which is our probiotic ointment in Czech Republic and Poland.
In addition, we had some key events in the quarter. We announced on August 31st that we are continuing our exclusive distribution agreement with Recordati in Spain and Portugal. As I said, we also announced the launch of our BioGaia Colus product, which is targeted for people to support colon health. And we have some clinical studies, as I said, also in the areas of acute, uncomplicated diverticulitis. And then on September 16th, we announced that we will be hosting a Capital Markets Day in London on December 8th. We will be holding both an in-person event in London, and the presentation will be broadcast live.
In terms of our different segments, as you can see here, pediatrics has grown 21% for the quarter, excluding currency effects, and adult health has grown 29% for the quarter. And as you can see over the past quarters, we have had strong growth each quarter in pediatrics as well as adult health, especially adult with strong double-digit growth. Getting a little bit further into the segments. As I said, pediatrics grew 21% and adult health 29% in the quarter. If you look at this year to date, pediatrics is growing 14%, excluding currency effects. And adult health is growing 23%. Specifically in pediatrics, our sales increased mainly in the US, China, and France, and our Protectis drops performed very well in the Americas and EMEA in adult health. Our Protectis tablets increased significantly and sales increased overall in Asia-Pacific and EMEA, mainly in Hong Kong and Italy. And if we now go into more detail in the regions, EMEA grew 38% for the quarter, excluding currency effects. Overall, year-to-date, that puts us at 26% growth for Europe, Middle East, and Africa; Asia Pacific in the quarter grew 8%, and overall that puts us at 2% growth, excluding currency effects. Year to date, the Americas grew 23% in the quarter, and overall year to date, EMEA grew 17%. Some of the highlights for the quarter are that sales increased, mainly in France, Poland, and Germany. We did communicate that we have some quarterly variations for individual orders where customers decided to move some of their orders from Q4 into Q3. For EMEA and Asia Pacific, as I said, the adult health segment grew, but the pediatric segment decreased. Sales for the quarter were mainly in China, South Korea and Japan. And in the Americas, some of the highlights are that both the pediatrics and adult health segments grew. The adult health segment grew, and sales increased mainly in the US, Canada, and Brazil. Overall, this puts us at 74% for pediatrics year to date. And you can see the breakdown of our year-to-date sales: 43% for the Americas, 35% for EMEA and Asia Pacific, and 22% for the rest of the world. I will now turn it over to Alexander Kotsinas to go through the financials in more detail.